October 11, 2017 10:26 AM EDT

Ultragenyx wins priority review for burosumab; Genfit raising €150M for PhIII NASH study

Shehla Shakoor

Managing Director

→ Ultragenyx $RARE and its partners at Kyowa Hakko Kirin landed a priority review for burosumab to treat pediatric and adult patients with X …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ultragenyx wins priority review for burosumab; Genfit raising €150M for PhIII NASH study

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ul­tragenyx wins pri­or­i­ty re­view for buro­sum­ab; Gen­fit rais­ing €150M for PhI­II NASH study

Managing Director

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Ultragenyx wins priority review for burosumab; Genfit raising €150M for PhIII NASH study